Activin and Inhibin

M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical ( IC 50 =3.6 nM) and cellular ( IC 50 =3.4 nM) potency against the LMP7 subunit. M3258 shows strong

M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical ( IC 50 =3.6 nM) and cellular ( IC 50 =3.4 nM) potency against the LMP7 subunit. M3258 shows strong

M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical ( IC 50 =3.6 nM) and cellular ( IC 50 =3.4 nM) potency against the LMP7 subunit. M3258 shows strong

M40 is a potent, non-selective galanin receptor antagonist.In VitroM40 (1 μM) displaces [mono[ 125 IJodo-Tyr 26 ]galanin from binding sites in the hippocampus, hypothalamus, and spinal cord. M40 has a lower affinity than galanin for all membranes.

M40 is a potent, non-selective galanin receptor antagonist.In VitroM40 (1 μM) displaces [mono[ 125 IJodo-Tyr 26 ]galanin from binding sites in the hippocampus, hypothalamus, and spinal cord. M40 has a lower affinity than galanin for all membranes.

M40 is a potent, non-selective galanin receptor antagonist.In VitroM40 (1 μM) displaces [mono[ 125 IJodo-Tyr 26 ]galanin from binding sites in the hippocampus, hypothalamus, and spinal cord. M40 has a lower affinity than galanin for all membranes.

M40 is a potent, non-selective galanin receptor antagonist.In VitroM40 (1 μM) displaces [mono[ 125 IJodo-Tyr 26 ]galanin from binding sites in the hippocampus, hypothalamus, and spinal cord. M40 has a lower affinity than galanin for all membranes.

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1In VitroM435-1279 (0, 2, 4, 8, 16, 31 μM: 48 h) significantly inhibits the growth of HGC27,

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1In VitroM435-1279 (0, 2, 4, 8, 16, 31 μM: 48 h) significantly inhibits the growth of HGC27,

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1In VitroM435-1279 (0, 2, 4, 8, 16, 31 μM: 48 h) significantly inhibits the growth of HGC27,

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1In VitroM435-1279 (0, 2, 4, 8, 16, 31 μM: 48 h) significantly inhibits the growth of HGC27,

M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1In VitroM435-1279 (0, 2, 4, 8, 16, 31 μM: 48 h) significantly inhibits the growth of HGC27,